“Tackling Corrupt Practices: GSK China ” by Meyer, K. in Peng, K. and Meyer, K. (2016) pp. 544 – 549

Read the case entitled: “Tackling Corrupt Practices: GSK China ” by Meyer, K. in Peng, K. and Meyer, K. (2016) pp. 544 – 549 and answer the following questions:

1. Using the “four risks of international business”, assess the risks facing GlaxoSmithKline (GSK) in doing business in China (40 marks)

2. With reference to the GSK China case study, identify and discuss the factors responsible for the corrupt practices in Chinese pharmaceutical/medical industry. In what various ways can the Chinese government discourage corrupt practices in the pharmaceutical/medical industry? (30 marks)

3. Explain how GlaxoSmithKline (GSK) can use Corporate Social Responsibility (CSR) and Corporate Governance Practices to tackle the corrupt practices in the Chinese Pharmaceutical/Medical Industry. What does GSK stand to gain from the implementation of CSR and Corporate Governance initiatives in its operations in China? (30 marks)

“PLACE THIS ORDER OR A SIMILAR ORDER WITH BRAINY TERM PAPERS AND GET AN AMAZING DISCOUNT”